SpiderRock Advisors LLC increased its stake in shares of Danaher Co. (NYSE:DHR – Free Report) by 26.5% in the third quarter, HoldingsChannel reports. The firm owned 17,862 shares of the conglomerate’s stock after buying an additional 3,742 shares during the period. SpiderRock Advisors LLC’s holdings in Danaher were worth $4,966,000 as of its most recent SEC filing.
A number of other institutional investors also recently added to or reduced their stakes in the stock. CarsonAllaria Wealth Management Ltd. bought a new stake in shares of Danaher in the 2nd quarter valued at about $25,000. nVerses Capital LLC purchased a new stake in Danaher during the second quarter valued at approximately $25,000. MFA Wealth Advisors LLC acquired a new stake in Danaher in the second quarter valued at approximately $51,000. Financial Connections Group Inc. purchased a new position in Danaher in the second quarter worth $51,000. Finally, Western Pacific Wealth Management LP acquired a new position in shares of Danaher during the first quarter worth $55,000. Institutional investors own 79.05% of the company’s stock.
Danaher Price Performance
Shares of NYSE DHR opened at $245.41 on Friday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The firm’s 50 day simple moving average is $264.89 and its 200-day simple moving average is $260.71. Danaher Co. has a 12 month low of $192.35 and a 12 month high of $281.70. The stock has a market capitalization of $177.25 billion, a price-to-earnings ratio of 46.83, a PEG ratio of 4.54 and a beta of 0.85.
Danaher Dividend Announcement
The firm also recently announced a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were paid a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. The ex-dividend date of this dividend was Friday, September 27th. Danaher’s payout ratio is 20.61%.
Wall Street Analysts Forecast Growth
A number of analysts have recently weighed in on the company. Wolfe Research raised Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective for the company in a research report on Thursday, October 31st. UBS Group lowered their price target on Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a report on Wednesday, October 23rd. Stifel Nicolaus boosted their price target on Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research note on Wednesday, October 23rd. Bank of America increased their price objective on shares of Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a research report on Wednesday, July 24th. Finally, TD Cowen lifted their target price on shares of Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research note on Wednesday, October 23rd. Five investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $287.16.
View Our Latest Research Report on DHR
Insider Activity
In other Danaher news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 10.90% of the company’s stock.
Danaher Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Further Reading
- Five stocks we like better than Danaher
- Top Stocks Investing in 5G Technology
- Dot Ai IPO: CEO Ed Nabrotzky Shares Vision for Logistics Future
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- The Hottest Markets to Watch After the Fed’s 25 Bps Rate Cut
- Canadian Penny Stocks: Can They Make You Rich?
- The Top 5 Performing S&P 500 Stocks YTD in 2024
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.